Gc1008    (DrugBank: GC1008)

2 diseases
IDDisease name (Link within this page)Number of trials
85Idiopathic interstitial pneumonia1
222Primary nephrotic syndrome4

85. Idiopathic interstitial pneumonia    [ 514 clinical trials,   377 drugs,   (DrugBank: 108 drugs),   97 drug target genes,   204 drug target pathways]
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 514 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00125385
(ClinicalTrials.gov)
July 200529/7/2005Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)Phase I, Open-Label, Multi-Center, Single-Dose, Dose-Escalating, Safety, Tolerability and Pharmacokinetic of GC1008 in Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisBiological: GC1008Genzyme, a Sanofi CompanyNULLCompleted18 Years79 YearsBoth25Phase 1United States;Belgium

222. Primary nephrotic syndrome    [ 234 clinical trials,   241 drugs,   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways]
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 234 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-002365-35-DE
(EUCTR)
15/07/201311/03/2013A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis Focal segmental glomerulosclerosis
MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify
Product Name: Fresolimumab
Product Code: GC1008
INN or Proposed INN: Fresolimumab
Other descriptive name: GZ402669
Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes
125Phase 2France;United States;Brazil;Spain;Germany;Italy
2EUCTR2012-002365-35-IT
(EUCTR)
22/05/201320/03/2013A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis Focal segmental glomerulosclerosis
MedDRA version: 15.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify
Product Name: Fresolimumab
Product Code: GC1008
INN or Proposed INN: Fresolimumab
Other descriptive name: GZ402669
Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes
125Phase 2France;United States;Brazil;Spain;Germany;Italy
3EUCTR2012-002365-35-ES
(EUCTR)
19/04/201309/04/2013A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis Focal segmental glomerulosclerosis
MedDRA version: 14.1;Level: PT;Classification code 10067757;Term: Focal segmental glomerulosclerosis;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Not possible to specify
Product Name: Fresolimumab
Product Code: GC1008
INN or Proposed INN: Fresolimumab
Other descriptive name: GZ402669
Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes
125Phase 2France;United States;Brazil;Spain;Germany;Italy
4NCT00464321
(ClinicalTrials.gov)
May 200720/4/2007Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGSA Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental GlomerulosclerosisBiological: GC1008Genzyme, a Sanofi CompanyNULLCompleted18 YearsN/ABoth16Phase 1United States;Germany;Italy;United Kingdom